18:38 , Feb 8, 2019 |  BioCentury  |  Finance

Extending a Bold vision for Longevity

After making a handful of longevity-related investments as a partner at Bold Capital, Sergey Young is seeking to invest about $100 million via the Longevity Vision Fund, a new vehicle dedicated solely to the field...
22:56 , Jan 9, 2019 |  BC Extra  |  Company News

Elevian, AI company Insilico partner to find anti-aging candidates in GDF11 pathway

Elevian Inc. (Allston, Mass.) partnered with AI company Insilico Medicine Inc. (Baltimore, Md.) to use deep-learning technology to discover small molecules that target the GDF11 pathway to treat age-related diseases. Insilico will apply its generative...
00:06 , Sep 28, 2018 |  BC Innovations  |  Emerging Company Profile

GDF11 against aging

Harvard University spinout Elevian Inc. is developing a regenerative platform around GDF11 to treat age-related diseases, including Alzheimer's disease. The company, which emerged from stealth on Sept. 6, aims to modulate the protein’s pathway with...
19:28 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Anti-aging Elevian debuts with $5.5M seed funding

Regenerative medicine company Elevian Inc. (Allston, Mass.) launched on Sept. 6 with $5.5 million in seed funding from Bold Capital, WTI, Stanford StartX fund, Longevity Fund, Kizoo Ventures, Thynk Capital and additional undisclosed investors. Elevian...
19:43 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
15:47 , Aug 30, 2018 |  BC Extra  |  Clinical News

Pfizer ends Phase II trials of DMD candidate

Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy after one of the studies missed its primary endpoint. The company will evaluate the data to determine next steps...
20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer...
20:41 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest inhibiting GDF11 could help treat osteoporosis. In a mouse model of estrogen deficiency-induced bone loss, an anti-GDF11 mAb increased the number, thickness and volume of trabeculae in the distal femur...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Clinical News

Acceleron Pharma Inc preclinical data

In mice, twice-weekly 10 mg/kg subcutaneous ACE-2494 increased muscle mass from baseline to week 4 by 40.9% in the rectus femoris, 53.3% in the gastrocnemius and 86.9% in the pectoralis vs. vehicle-treated controls (p?0.01 for...
01:21 , Jun 20, 2014 |  BC Extra  |  Top Story

J&J Innovation inks new deals

Johnson & Johnson (NYSE:JNJ) announced 10 new deals out of its regional innovation centers. Among the deals, the London innovation center partnered with Minerva Neurosciences Inc. (Cambridge, Mass.) to develop MIN-202, an orexin 2 receptor...